Integrated immune gene expression signature and molecular classification in gastric cancer: New insights. Issue 2 (14th March 2020)

• Record Type: Journal Article
• Authors: Refolo, Maria Grazia; Lotesoriere, Claudio; Messa, Caterina; Caruso, Maria Gabriella; D'Alessandro, Rosalba
• Is Part Of: Journal of leukocyte biology. Volume 108:Issue 2(2020)
• Page Start: 633
• Page End: 646
• Publication Date: 2020-03-14
• Subjects: angiogenesis -- gastric cancer -- immunotherapy -- tils -- VEGFA; Leucocytes -- Periodicals; Reticulo-endothelial system -- Periodicals; 571.96
• DOI: 10.1002/JLB.4MR0120-221R
• Languages: English
• ISSNs: 0741-5400

Abstract

Abstract: Gastric cancer (GC) is characterized by extreme heterogeneity due to histopathological differences, molecular characteristics, and immune gene expression signature. Until recently, several targeted therapies failed due to this complexity. The recent immunotherapy resulted in more effective and safe approaches in several malignancies. All tumors could be considered potentially immunogenic and the new knowledge regarding the interactions among tumor cells, immune cells, and tumor microenvironment (TME) allowed to reverse possible immune resistance. The immune response is a complex multisteps process that finely regulates the balance between the recognition of non‐self and the prevention of autoimmunity. Cancer cells can use these pathways to suppress tumor immunity as a major mechanism of immune resistance. The recent molecular classifications of GCs by The Cancer Genome Atlas (TCGA) and by the Asian Cancer Research (ACRG) networks, together with the identification of multiple biomarkers, open new perspectives for stratification of patients who might benefit from a long‐term immune checkpoint therapy. One of the major processes that contribute to an immunosuppressive microenvironment is represented by tumor angiogenesis. The cellular mechanisms inducing both angiogenesis and immunosuppressive responses are often reached by the same cell types and soluble factors, such as vascular endothelial growth factor A (VEGFA). Recent studies point out that combinatorial strategies should be adapted as useful therapeutic approach to reverse the immunosuppressive status of microenvironment occurring in a relevant percentage of gastric tumors. Graphical Abstract: Review on the relationship between tumor, immune cells, and tumor microenvironment and strategies to overcome resistance mechanisms that complicate gastric cancer therapies.